 | ||||||
GSK plc 980 Great West Road Brentford Middlesex TW8 9GS T +44 (0)20 8047 5000 |
March 10, 2023
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen,
Re: Notice of disclosure filed in Securities Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that GSK plc has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on March 10, 2023. The disclosure can be found on page two of the Annual Report on Form 20-F, which incorporates by reference the information set forth under the heading “Section 13(r) of the US Exchange Act” on page 305 of Exhibit 15.2 to the Annual Report on Form 20-F, and is incorporated by reference herein.
Respectfully submitted,
| GSK plc | ||
| By: | /s/ Iain Mackay | |
| Name: | Iain Mackay | |
| Title: | Chief Financial Officer | |
Registered in England & Wales Company Number: 03888792 | Registered Office: 980 Great West Road, Brentford, Middlesex, TW8 9GS |